Saturday, 7 December 2013

MediPoint: Cardiac Rhythm Management - APAC Analysis and Market Forecasts

Reportstack has announced a new market report on MediPoint: Cardiac Rhythm Management - APAC Analysis and Market Forecasts. Cardiac rhythm management (CRM) comprises any method of treatment aimed at regulating the heart’s rhythm, including medication, medical devices, and occasionally surgery. There can be a number of reasons why CRM is needed, all of which generally involve malfunctions of the heart’s electrical system, and are related to cardiac dyssynchrony. While medication can be effective in mild to moderate cases, patients with more severe conditions must turn to device use or surgical intervention in order to receive the therapy they require. Over the years, CRM device treatment has become less invasive, and significant advances in pacing and pulse generator technology have enabled effective long-term device therapy with limited complications.

Across the three countries included in this report, there is a marked heterogeneity in the pacemaker implantation rate per million inhabitants. Moreover, there is also a large gap among the countries in the number of pacemaker-implanting centers per million inhabitants.

Scope

- An overview of hypertension, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized APAC CRM market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for CRM
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the CRM sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

- Understand the trends shaping and driving APAC CRM market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in APAC CRM market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What’s the next big thing in APAC CRM market landscape? Identify, understand and capitalize.

The Companies Mentioned in this report are: Biotronik Boston Scientific Impulse Dynamics Medtronic Sorin Group St. Jude Medical.

To view the table of contents and know more details please visit MediPoint: Cardiac Rhythm Management - APAC Analysis and Market Forecasts report.

Thursday, 5 December 2013

Esophageal Cancer Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on Esophageal Cancer Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on Esophageal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Esophageal Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit Esophageal Cancer Global Clinical Trials Review, H2, 2013 report.

Gastric Cancer Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on Gastric Cancer Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on Gastric Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastric Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit Gastric Cancer Global Clinical Trials Review, H2, 2013 report.

High Triglyceridemia Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on High Triglyceridemia Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on High Triglyceridemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating High Triglyceridemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit High Triglyceridemia Global Clinical Trials Review, H2, 2013 report.

Laryngeal Cancer Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on Laryngeal Cancer Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on Laryngeal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Laryngeal Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit Laryngeal Cancer Global Clinical Trials Review, H2, 2013 report.

Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on Left Ventricular Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Left Ventricular Dysfunction. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2013 report.

Ovarian Cancer Global Clinical Trials Review, H2, 2013

Reportstack has announced a new market report on Ovarian Cancer Global Clinical Trials Review, H2, 2013 which provides elemental information and data relating to the clinical trials on Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ovarian Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

To view the table of contents and know more details please visit Ovarian Cancer Global Clinical Trials Review, H2, 2013 report.